GW3965 HCl

For research use only. Not for use in humans.

目录号:S2630

GW3965 HCl Chemical Structure

CAS No. 405911-17-3

GW3965 HCl是一种有效的,选择性LXR激动剂,作用于hLXRα和hLXRβ,无细胞试验中EC50分别为190和30 nM。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1966.57 现货
RMB 790.51 现货
RMB 4654.57 现货
RMB 9746.1 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的GW3965 HCl发表文献30篇:

产品安全说明书

Liver X Receptor抑制剂选择性比较

生物活性

产品描述 GW3965 HCl是一种有效的,选择性LXR激动剂,作用于hLXRα和hLXRβ,无细胞试验中EC50分别为190和30 nM。
靶点
hLXRβ [1]
(Cell-free assay)
LXRα/SRC1 LiSA [1]
(Cell-free assay)
hLXRα [1]
(Cell-free assay)
30 nM(EC50) 125 nM(EC50) 190 nM(EC50)
体外研究

GW3965使类固醇受体共激活因子1聚集到LXRα,在无细胞配体检测试验中,EC50 为125 nM。[1] GW3965对hLXRα 和 hLXRβ表现出有效的拮抗活性,在细胞试验中EC50分别为190 nM 和30 nM。此外,GW3965也对其他核受体表现出优良的选择性。[1]在人胰岛中,GW3965 (1 μM)降低选定促炎性细胞因子,包括IL-8,单核细胞趋化蛋白-1和组织因子的表达。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 NXv0U4dxOTBidV2= NV;1c3dwOjBiaILz Mli3RYN1cX[jdHnvckBw\iCqdX3hckBNYFKjbIDoZUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJINwNWW6cILld5NqdmdiaIXtZY4hWliUYXzwbIEh[XRiMUCgeW0h[W[2ZYKgNlAhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NVXNS|dzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwNFY6ODlpPkK4NFA3QTB7PD;hQi=>
HEK293 NW\wcopsOTBidV2= NGf1T3EzOCCqcoO= NUnRfFJpSWO2aY\heIlwdiCxZjDyZZQhVFiUYnX0ZUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJINwNWW6cILld5NqdmdiaIXtZY4hWliUYXzwbIEh[XRiMUCgeW0h[W[2ZYKgNlAhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? M{XnOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEC2PVA6Lz5{OECwOlkxQTxxYU6=
THP1 NXe5dYk{TnWwY4Tpc44h[XO|YYm= MnryTY5lfWO2aX;uJI9nKGOqb3zld5Rmem:uIHXm[ox2gCCrbjDUTHAyKGOnbHzzMEBGSzVyIE2gNE4xOSEQvF2u Mle5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3OEe1O|MoRjF5NUi3OVc{RC:jPh?=
THP1 MlXISpVv[3Srb36gZZN{[Xl? Mo\5NVghcHK| NYW1XXcyUW6mdXP0bY9vKG:oIHPoc4xme3Sncn;sJIVn\my3eDDpckBVUFBzIHPlcIx{KGGodHXyJFE5KGi{czygSWM2OCB;IECuNFEh|ryPLh?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRzNkWyNUc,OTd2MU[1NlE9N2F-
COS7 M2LQcGZ2dmO2aX;uJIF{e2G7 NHjzPJgyPiCqcoO= M13JNWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gUHhT[mW2YTDy[YNmeHSxcjD0doFve2[nY4Tl[EBqdiCFT2O3JINmdGy|IHHmeIVzKDF4IHjyd{BjgSC{ZYDvdpRmeiC2cnHud4FkfGm4YYTpc44h[XO|YYmsJGVEPTBiPTCwMlAyPSEQvF2u MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV6N{W3N{c,OTd3OEe1O|M9N2F-
COS7 MlK1SpVv[3Srb36gZZN{[Xl? MVXBZ5RqfmG2aX;uJI9nKEy[UnLleIEh[29vdILhcpNn\WO2ZXSgbY4hS0:VNzDj[YxteyC5aYToJHJZWmGucHjhJIJ6KHKncH;yeIVzKHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OCB;IECuNFE2KM7:TT6= M3T2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEG2OVIyLz5zN{SxOlUzOTxxYU6=
THP1 MUHBcpRqcW6obHHtcYF1d3K7IHHzd4F6 M1vLOFYhcHK| NUD2fGltSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGTIVFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCLTE[gdJJw\HWldHnvckBi\nSncjC2JIhzeyCkeTDFUGlUSSxiSVO1NEA:KDBwMEKg{txONg>? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDhyMEe2O{c,OTh6MEC3Olc9N2F-
THP1 MXXGeY5kfGmxbjDhd5NigQ>? NVnz[JgzSWexbnnzeEBi[3Srdnn0fUBifCCJQVytcIlvc2WmIHj1cYFvKEy[UnLleIEh\XiycnXzd4VlKGmwIGTIVFEh[2WubIOgZZN{\XO|ZXSgZZMhe3SrbYXsZZRqd25ib3[gZ48u[WO2aY\heI9zKHKnY4L1bZRu\W62IHL5JGZTTVRiYYPzZZktKEWFNUCgQUAxNjB{NzFOwG0v M{LuUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nk[1PFk4Lz5zN{[2OVg6PzxxYU6=
RAW264.7 NUfTUYNLTnWwY4Tpc44h[XO|YYm= MXuyOEBpenN? NULLXFk2UW6mdXP0bY9vKG:oIGuzTH1kcG:uZYP0[ZJwdCCnZn\seZghcW5ibX;1d4UhWkGZMk[0Mlch[2WubIOgcI9i\GWmIIfpeIgh[WOndInsZZRm\C2ORFygZYZ1\XJiMkSgbJJ{NCCHQ{WwJF0hOC5yMkmg{txONg>? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTdzN{OwOEc,OTl5MUezNFQ9N2F-
THP1 NXe1eG9ITnWwY4Tpc44h[XO|YYm= NWPycWxzW3SrbYXsZZRqd25ib3[gX|NJZWOqb3zld5Rmem:uIHXm[ox2gCCrbjDoeY1idiCWSGCxJIZw[W1iY3XscJMhdG:jZHXkJJdqfGhiYXOtUGRNNCCHQ{WwJF0hOC5yM{Gg{txONg>? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl5M{K4PEc,OTh7N{OyPFg9N2F-
CV1 MXLGeY5kfGmxbjDhd5NigQ>? NFnzOIlCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFzYVoJmfGFibHnnZY5lKGKrbnTpcoch\G:vYXnuJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gWFE{OTdvaX7keYNm\CC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkhcW5iYX\ybYNidiCpcnXlckBud26tZYmgR3YyKGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIghT2GuND3TVmMyKGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKgZZN{[XluIFnDOVAhRSByLkCzPVgyKM7:TT6= NHjNd249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO0OVExOid-MkCzOFUyODJ:L3G+
THP1 NY\IUWpiTnWwY4Tpc44h[XO|YYm= NEn2dG9C\2:waYP0JIFkfGm4aYT5JIF1KEeDTD3sbY5s\WRiaIXtZY4hVFiUYXzwbIEh\XiycnXzd4VlKGmwIGTIVFEh[2WubIOgZZN{\XO|ZXSgZZMhe3SrbYXsZZRqd25ib3[gZ49i[3SrdnH0c5IhemWlcoXpeI1mdnRiYomgSnJGXCCjc4PhfUwhTUN3MDC9JFAvODl5IN88UU4> NVnES3NSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2OlU5QTdpPkG3OlY2QDl5PD;hQi=>
CV1 NGHwXHFHfW6ldHnvckBie3OjeR?= MkDWRY51[WexbnnzeEBi[3Srdnn0fUBifCCOWGLhcJBp[SCuaXfhcoQh[mmwZHnu[{Bld22jaX6gZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDUNVMyPy2rbnT1Z4VlKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBqdiCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDDWlEh[2WubIOgZ48ufHKjboPm[YN1\WRid3n0bEBI[Wx2LWPSR|Eh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDhd5NigSxiSVO1NEA:KDBwMTFOwG0v MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN2NUGwNkc,OjB|NEWxNFI9N2F-
SH-SY5Y NUD6ZoE6TnWwY4Tpc44h[XO|YYm= MXiyOEBpenN? Mkm2RYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDMXHJj\XSjIHX4dJJme3OnZDDpckBpfW2jbjDTTE1UYTW\IHPlcIx{KGOxLYTyZY5{\mWldHXkJJdqfGhiR3HsOE1NSkRiYX\0[ZIhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OCB;IECuNVMh|ryPLh?= MmjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{NkS0PFEoRjF7Mk[0OFgyRC:jPh?=
HepG2 MmXYSpVv[3Srb36gZZN{[Xl? MXXF[oZm[3Rib36gV3JGSlBzYzDn[Y5mKGW6cILld5Nqd25iaX6gbJVu[W5iSHXwS|Ih[2WubIOsJGVEPTBiPTCwMlIyKM7:TT6= NXXJ[|k5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5O|MzQDhpPkG4PVc{Ojh6PD;hQi=>
HuH7 MULGeY5kfGmxbjDhd5NigQ>? MYHB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIILlZ49u[mmwYX70JGxZWmKndHGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKGmwIHj1cYFvKEi3SEegZ4VtdHNiY3:teJJidnOoZXP0[YQhf2m2aDDmeZNm\CCJYXy0MWRDTCCkeTD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUCgQUAxNjNzIN88UU4> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl5M{K4PEc,OTh7N{OyPFg9N2F-
SH-SY5Y NWjJNoNjTnWwY4Tpc44h[XO|YYm= MmXZNlQhcHK| MYTB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIFzYVoFteGijIHX4dJJme3OnZDDpckBpfW2jbjDTTE1UYTW\IHPlcIx{KGOxLYTyZY5{\mWldHXkJJdqfGhiR3HsOE1NSkRiYX\0[ZIhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OCB;IECuN|Eh|ryPLh?= NIfTeIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUK2OFQ5OSd-MUmyOlQ1QDF:L3G+
CHO M1\DV2Z2dmO2aX;uJIF{e2G7 NGjUO4xC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJGxZWiCkZYThJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYomgdoVxd3K2ZYKgZZN{[XluIFXDOVAhRSByLkSxJO69VS5? MlXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyM{SxNVkoRjF5MEO0NVE6RC:jPh?=
CHOK1 NWTIRppCTnWwY4Tpc44h[XO|YYm= Mn\5NlQhcHK| NEXVcmhC\2:waYP0JIFkfGm4aYT5JIF1KEejbESteIFo\2WmIFzYVoJmfGFiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gR2hQUzFiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwNEKg{txONg>? M4L2b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nke3OlY1Lz5{NU[3O|Y3PDxxYU6=
THP1 Mmn0SpVv[3Srb36gZZN{[Xl? NV7BTZdFTW[oZXP0JI9vKEGEQ1GxJIdmdmViZYjwdoV{e2mxbjDpckBpfW2jbjDkbYZn\XKnboTpZZRm\CCWSGCxJINmdGy|LDDFR|UxKD1iMD60N|Qh|ryPLh?= NHfydmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEm3N|I5QCd-MUi5O|MzQDh:L3G+
CV1 M4LCXmZ2dmO2aX;uJIF{e2G7 NWX4UWM4SWexbnnzeEBi[3Srdnn0fUBifCCOWGLi[ZRiKGyrZ3Hu[EBjcW6maX7nJIRwdWGrbj3t[YRq[XSnZDD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliaX6gZYZzcWOjbjDndoVmdiCvb37r[ZkhS1ZzIHPlcIx{KGOxLYTyZY5{\mWldHXkJJdqfGhiR3HsOE1UWkNzIHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh[XO|YYmsJGVEPTBiPTCwMlUxOTF7IN88UU4> NEfZRWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO0OVExOid-MkCzOFUyODJ:L3G+
HuH7 NHrWUXpHfW6ldHnvckBie3OjeR?= M4Pq[mFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gdoVkd22kaX7hcpQhVFiUYXzwbIEhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHnuJIh2dWGwIFj1TFch[2WubIOgZ48ufHKjboPm[YN1\WRid3n0bEBnfXOnZDDHZYw1NUSERDDifUB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVAhRSByLk[2JO69VS5? NXvVOnlPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5O|MzQDhpPkG4PVc{Ojh6PD;hQi=>
CV1 MVTGeY5kfGmxbjDhd5NigQ>? MkfQRYdwdmm|dDDhZ5Rqfmm2eTDheEBNYFKjbIDoZUBtcWejbnSgZolv\GmwZzDkc41icW5vbXXkbYF1\WRidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGmwIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNXOSClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKEejbEStV3JEOSCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIF{e2G7LDDFR|UxKD1iMD63PVQ{OyEQvF2u MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN2NUGwNkc,OjB|NEWxNFI9N2F-
CHOK1 NYP3UZhXTnWwY4Tpc44h[XO|YYm= M2Htd|I1KGi{cx?= NEnk[G9C\2:waYP0JIFkfGm4aYT5JIF1KEejbESteIFo\2WmIFzYVoFteGijIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGNJV0tzIHPlcIx{KGGodHXyJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSBzLkOg{txONg>? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ5N{[2OEc,OjV4N{e2OlQ9N2F-
HepG2 Mn;ySpVv[3Srb36gZZN{[Xl? NIrOOZZG\m[nY4Sgc44hfHKrZ3z5Z4VzcWSnIHHjZ5VufWyjdHnvckBqdiCqdX3hckBJ\XCJMjDj[YxteyxiRVO1NEA:KDJwMECyJO69VS5? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl5M{K4PEc,OTh7N{OyPFg9N2F-
HepG2 Mlj6SpVv[3Srb36gZZN{[Xl? Mn3COVAxKG6P MmXwTY5pcWKrdHnvckBw\iB{LTizMUg{NShqMj3jbIxwem9vMz2oeJJq\my3b4LvcYV1cHmuKXLlcpp6dClqMjyyMYRqeGinbons[ZRpgWxrYX3pco8qeHKxcH;4fUlxcGWweXypZYNmfGmlIHHjbYQucW6mdXPl[EB{emWkcEHjJI1TVkFiZYjwdoV{e2mxbjDpckBpfW2jbjDI[ZBIOiClZXzsd{BifCB3MECgcm0> MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDhyMEe2O{c,OTh6MEC3Olc9N2F-
HepG2 MnLrSpVv[3Srb36gZZN{[Xl? M{PyT|UxOCCwTR?= NY\jZZBuUW6qaXLpeIlwdiCxZjCyMUg{NSh|LTioNk1kcGyxcn:tN{0pfHKrZnz1c5JwdWW2aInsLYJmdnq7bDmoNkwzNWSrcHjlcplt\XSqeXypZY1qdm9rcILvdI95gSmyaHXufYwq[WOndHnjJIFkcWRvaX7keYNm\CCoYYOgcXJPSSCneIDy[ZN{cW:wIHnuJIh2dWGwIFjldGczKGOnbHzzJIF1KDVyMDDuUS=> NVn5XZNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4NFA4PjdpPkG4PFAxPzZ5PD;hQi=>
RAW264.7 Mn;vSpVv[3Srb36gZZN{[Xl? Mn[zNUB2VQ>? MWjS[YR2[3Srb36gc4YhVFCVLYP0bY12dGG2ZXSgbW5QWyCpZX7lJIV5eHKnc4Ppc44hcW5ibX;1d4UhWkGZMk[0Mlch[2WubIOg[ZhxemW|c3nu[{BNYFKjbIDoZUBifCBzIIXNJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeR?= NEi1NpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEiwNFc3Pyd-MUi4NFA4Pjd:L3G+
RAW264.7 NWnCXoIyTnWwY4Tpc44h[XO|YYm= NVf2XmRXOSC3TR?= NYixeGl7UW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCwdXPs[YFzKGOxLYLldJJme3OxcjDy[Yxm[XOnIH\yc40hcU6RUzDwdo9ud3SncjDpckBud3W|ZTDSRXczPjRwNzDj[YxteyCjdDCxJJVOKGK7IGLUMXBEWg>? M1jnVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OECwO|Y4Lz5zOEiwNFc3PzxxYU6=
HeLa Mlq4SpVv[3Srb36gZZN{[Xl? NID6RYoyKHWP NGDQUHNKdmS3Y4Tpc44hd2ZiTGjSZoV1[SCVVV3PfYxifGmxbjDifUBUXU2RMjDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDFidV2gZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NEG1[Fk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEiwNFc3Pyd-MUi4NFA4Pjd:L3G+
HeLa MXnGeY5kfGmxbjDhd5NigQ>? MlnGNUB2VQ>? NGPoZXNKdmS3Y4Tpc44hd2ZiTGjSZoV1[SCVVV3PfYxifGmxbjDifUBUXU2RMzDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDFidV2gZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| Mn25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6MEC3OlcoRjF6OECwO|Y4RC:jPh?=
HeLa MnXkSpVv[3Srb36gZZN{[Xl? MYKxJJVO NXjGbnNFUW6mdXP0bY9vKG:oIFzYVoFteGijIGPVUW96dGG2aX;uJIJ6KFOXTV:zJIlvKGi3bXHuJGhmVGFiY3XscJMh[XRiMTD1UUBjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= M{fPOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OECwO|Y4Lz5zOEiwNFc3PzxxYU6=
DAOY NFPnPJNyUFSVIHHzd4F6 NFXqS|ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?= NGnxT4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 MWLxTHRUKGG|c3H5 M1WwXZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz M3rYelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 M{XKdZFJXFNiYYPzZZk> NH\pXnpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= NEfhTng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NIPOenhyUFSVIHHzd4F6 NHf1cppyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 NGXFPXhyUFSVIHHzd4F6 MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MnK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 NEXFRlByUFSVIHHzd4F6 M1u5fZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz M1r5PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH NGTRUFdyUFSVIHHzd4F6 MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= M1;xfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 NWTWTGFleUiWUzDhd5NigQ>? NELsOG9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= MoLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 M1zFfpFJXFNiYYPzZZk> NI\sVIhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz M1vuSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD NVrtTYl1eUiWUzDhd5NigQ>? MmXKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ NG\NOHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) MkfLdWhVWyCjc4PhfS=> NIDBcnRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= NHLvWZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 NHG3UVRyUFSVIHHzd4F6 M1W3fpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy| M3juS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 NWHz[ZVSeUiWUzDhd5NigQ>? Mk\qdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? NETp[5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Skp2 / pEGFR / EGFR / pERK / ERK ; 

PubMed: 25184494     


GW3965 treatment downregulates SKP2 and EGFR protein levels in BxPC-3 and MIA-PaCa-2 cells. Downregulation of EGFR was concomitant with a downregulation of its own phosphorylation in BxPC-3 and MIA-PaCa-2 at 5 uM GW 3965. ERK1/2 and its phosphorylation were not statistically different in any of the cell lines.

LXRα / LXRβ / ABCA1 / ABCG1; 

PubMed: 11604492     


Differentiated THP-1 macrophages were incubated for 48 h in RPMI medium plus 10% LPDS, Oxysterols [20(S)HC, 22(R)HC, or 22(S)HC, 2.0 μg/ml], synthetic LXR ligand (GW3965 or T1317, 0.1 to 10.0 μM), or RXR ligand (LG268, 50 nM).

25184494 11604492
Immunofluorescence
LAMP-1 / LDLR; 

PubMed: 23382078     


HeLa cells were cultured in 10% LPDS medium for 8 h and then treated with GW3965 (1 μM) for the indicated times. Cells were immunostained with LDLR and LAMP-1 antibodies. Nuclei were counterstained with DAPI (blue). Representative confocal images are shown. T, time; O/N, overnight.

pRelA ; 

PubMed: 26635040     


Freshly isolated PDC (plasmacytoid dendritic cells) were treated for 24 h with 1 mM of GW3965 (GW), followed by TLR7 ligand, R848 (1 mg/mL) for 45 min. Phosphorylation of the NF-κB p65 (pRelA) subunit and its cellular localization were evaluated by confocal microscopy analysis. Results from a representative experiment out of 3 using PDC from 3 different donors.

23382078 26635040
Growth inhibition assay
Cell viability; 

PubMed: 25184494     


A, B, C, PDAC cells (BxPC-3, Mia-PaCa-2, and PANC-1 cell lines, respectively) show dose-dependent decreases in cell proliferation upon treatment with increasing GW3965 concentrations. EC50 calculations indicate that BxPC-3 and Mia-PaCa-2 cells are more sensitive to ligand treatment than PANC-1 cells. 

25184494
体内研究 在小鼠体内,GW3965在10 mg/kg剂量下使ABCA1表达上调8倍,并使循环水平提高30%,Cmax为12.7 μg/mL ,t1/2为2小时。[1] 在LDLR−/−和apoE−/−小鼠体内,GW3965 (10mg/kg)诱导ABCA1 和ABCG1表达,并表现出有效的抗动脉粥样硬化活性。[2]在雄性sprague-dawley大鼠体内,GW3965降低Ang II介导的血压增加,并减少血管Ang II受体基因表达。[3]在恶性胶质瘤小鼠模型中,GW3965导致LDLR降解,增加ABCA1胆固醇外排转运体的表达,从而有效促进肿瘤细胞死亡。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[1]
- 合并
  • Animal Models: C57BL/6 小鼠
  • Dosages: ≤10 mg/kg
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 16 mg/mL warmed (25.86 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 618.51
化学式

C33H31ClF3NO3.HCl

CAS号 405911-17-3
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to formulate the compound for mouse in vivo experiment?

  • 回答:

    S2630 GW3965 HCl can be dissolved in 2% DMSO/30% PEG 300/dd H2O at 10 mg/mL as a homogeneous suspension. This vehicle is suitable for oral gavage to mice.

相关Liver X Receptor产品

Tags: 购买GW3965 HCl | GW3965 HCl供应商 | 采购GW3965 HCl | GW3965 HCl价格 | GW3965 HCl生产 | 订购GW3965 HCl | GW3965 HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID